Codexis

Codexis, Inc. is an enzyme engineering company, which engages in the development and sale of therapeutics. It operates through the Performance Enzymes and Novel Biotherapeutics segments. The Performance Enzymes segment commercializes CodeEvolver protein engineering technology platform and products in the pharmaceuticals market. The Novel Biotherapeutics segment targets new opportunities to discover and improve biotherapeutic drug candidates. Its products include screening kits and Codex HiFi Hot Start DNA Polymerase. The company was founded in January 2002 and is headquartered in Redwood City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Codexis reports strong 2022 performance, eyes growth in Life Sciences

Codexis made significant progress in 2022, focusing on high-value programs and enhancing technical capabilities.
While facing challenges in managing expenses and revenue variability, the company is well-positioned with a strong cash position and growth opportunities.
Strategic collaborations and revenue diversification efforts position Codexis for sustainable growth and value creation in the future.

Codexis navigates revenue challenges, eyes growth through strategic partnerships

Codexis is strategically focusing on the ECO Synthesis platform and pharmaceutical manufacturing business for revenue growth and positive cash flow by 2026.
While facing challenges such as impairments on investments and revenue timing, the company is leveraging opportunities through partnerships and operational improvements.
The company's financial discipline, strong balance sheet, and key collaborations position it well for future growth and success in the pharmaceutical manufacturing sector.
With ongoing negotiations and advancements in technology, Codexis is poised for continued progress and innovation in the enzymatic solutions market.

Codexis reports robust Q4 performance, eyes growth through strategic partnerships

Codexis delivered a strong performance in Q4 2023, driven by strategic decisions, partnerships, and financial results showcasing growth potential.
The company's focus on expanding the ECO Synthesis platform and pharmaceutical manufacturing bodes well for sustained revenue growth.
While facing challenges in scaling operations and managing expenses, Codexis is well-positioned to capitalize on market opportunities and drive innovation.

Codexis projects 10% revenue growth, advances in RNA synthesis

Codexis is poised for growth in 2024, with a focus on revenue expansion, product innovation, and strategic partnerships to drive market success.
The company's strong performance in supplying enzymes for various programs underscores its market leadership and technological capabilities.
While facing challenges in diversifying its customer base and sustaining growth, Codexis is leveraging its strengths in technology and innovation to seize emerging opportunities.

Codexis reports Q3 revenue growth, eyes profitability amid strategic investments

Codexis navigates Q3 2024 with revenue growth in pharma manufacturing and strategic investments for future profitability.
Despite a net loss, the company maintains financial stability with a strong cash position and a focus on enhancing capabilities.
Challenges lie in achieving profitability by 2026, managing divestiture impacts, and optimizing gross margins amid operational changes.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Codexis Inc (NASDAQ: CDXS) raised its guidance for 2021 following the receipt of a binding purchase order for up to $13.9 million of a proprietary high-performance enzyme product from an undisclosed pharmaceutical company. Now, the Company expects 2021 total revenues in the range of $89 million to $93 million, up from previous guidance of $82 million to $85 million, higher than the $83.7 million consensus.

Codexis Raises 2021 Revenue Outlook After New Order For Its Enzyme Product

REDWOOD CITY, Calif., June 17, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, is raising its guidance for 2021, following the receipt of a binding purchase order for up to $13.9 million of a proprietary high performance enzyme product from an undisclosed global pharmaceutical company. The majority of this order was not included in Codexis' prior guidance for 2021; accordingly, the Company is raising its 2021 guidance for total revenues to a range of $89 million to $93 million, up from previous guidance of $82 million to $85 million. Codexis is also increasing its 2021 guidance for product revenue to a range of $45 million to $48 million, up from previous guidance of $36 million to $39 million. In addition, the Company is raising 2021 guidance for product gross margin to a range of 60% to 64%, up from previous guidance of 54% to 58%.

Codexis Raises 2021 Guidance Following Receipt of Significant New Order for a Proprietary Enzyme Product

REDWOOD CITY, Calif., June 10, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc., a leading enzyme engineering company enabling the promise of synthetic biology, today announced the expansion of its strategic collaboration and license agreement with Takeda Pharmaceutical Company Limited (“Takeda”) for the research and development of an additional gene therapy for a lysosomal storage disorder bringing the total number of programs under the agreement to four.

Codexis and Takeda Expand Strategic Collaboration and License Agreement to Discover Additional Gene Therapy for a Fourth Rare Genetic Disorder

Codexis, Inc. (CDXS) CEO John Nicols on Q1 2021 Results - Earnings Call Transcript

Total Revenue up 23% and Product Revenue Doubles Year over Year

Codexis Reports First Quarter 2021 Financial Results

REDWOOD CITY, Calif., April 22, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the first quarter of 2021 on Thursday, May 6, 2021, following the close of market. Codexis management will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the Company's financial results and provide a business update.

Codexis to Report First Quarter 2021 Financial Results on May 6

AstraZeneca

Bumble

McDonald's

Microsoft

Crown Castle International

International Flavors & Fragrances

Motorola Solutions

Radius Global Infrastructure Inc

With the trading day about halfway over, the broad markets were pulling back. All the major averages were reeling, especially the Nasdaq, on concerns over the global semiconductor shortage.

AstraZeneca, Bumble, McDonald's, Microsoft and More Monday Afternoon Analyst Calls

A Relative Strength Rating upgrade for Codexis shows improving technical performance. Will it continue?

Codexis Getting Closer To Key Technical Benchmark

Codexis, Inc.'s (CDXS) CEO John Nicols on Q4 2020 Results - Earnings Call Transcript

Shares of Codexis (NASDAQ:CDXS) fell in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 500.00% year over year to ($0.06), which beat the estimate of ($0.12).

Codexis: Q4 Earnings Insights

Strong Product Revenue Momentum in Second Half of 2020 Drives Company's Seventh Consecutive Year of YOY Revenue Growth

Codexis Reports Fourth Quarter and Fiscal Year 2020 Financial Results

REDWOOD CITY, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company, today announced that management will present at three upcoming virtual investment conferences.

Codexis to Present at Upcoming Virtual Healthcare Conferences

REDWOOD CITY, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company, today announced that it will report fourth quarter and full year 2020 financial results on Thursday, February 25, 2021, following the close of market. Codexis management will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the Company's financial results and provide a business update.

Codexis to Report Fourth Quarter and Full Year 2020 Results on February 25

REDWOOD CITY, Calif., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company, announced today it will be expanding its operations into a new 36,000 square foot facility in San Carlos, CA under a ten year lease. This facility will provide space for additional research and development laboratories and related office space.

Codexis Announces Expansion to New Facility to Accommodate Next Stage of Growth

REDWOOD CITY, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company, today announced the appointment of Esther Martinborough, Ph.D., to its board of directors, expanding its membership to ten directors.

Codexis Appoints Dr. Esther Martinborough to its Board of Directors

REDWOOD CITY, Calif. and HOFFMANN ESTATES, Ill., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company and developer of high-performance enzymes, and Tate & Lyle (LSE: TATE.L), a leading global provider of food ingredients and solutions, have extended and deepened their relationship to enhance the production of two of Tate & Lyle's newest sweeteners: DOLCIA PRIMA® Allulose and TASTEVA® M Stevia Sweetener.

Codexis Introduces Improved Enzymes to Further Enhance Tate & Lyle's Stevia and Allulose Production

REDWOOD CITY, Calif., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading protein engineering company, today announced the pricing of an underwritten public offering of 4,285,715 shares of its common stock at a public offering price of $17.50 per share. Net proceeds to Codexis from the offering are expected to be approximately $70.2 million after underwriting discounts and commissions and estimated offering expenses. The offering is expected to close on or about December 7, 2020, subject to customary closing conditions. Codexis has granted the underwriters of the offering the right for a period of 30 days to purchase up to an additional 642,857 shares of common stock at the public offering price, less underwriting discounts and commissions.

Codexis Announces Pricing of Public Offering of Common Stock

REDWOOD CITY, Calif., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading protein engineering company, today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares to be sold in the offering will be offered by Codexis. In addition, Codexis intends to grant to the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering, on the same terms and conditions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.

Codexis Announces Proposed Public Offering of Common Stock

C ombine s Codexis' R&D and commercialization platform with Casdin Capital 's investment expertise to invest in and support innovative early stage life science and synthetic biology technology companies

Codexis and Casdin Capital Launch SynBio Innovation Accelerator

REDWOOD CITY, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company, announces that management will participate at three upcoming virtual investment conferences:

Codexis to Participate at Three Virtual Investment Conferences in November

Codexis, Inc. (CDXS) CEO John Nicols on Q3 2020 Results - Earnings Call Transcript

REDWOOD CITY, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company, announces that it will report third quarter 2020 financial results after market close on Thursday, November 5, 2020. Codexis management will hold an investment community conference call at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss financial results and provide a company update.

Codexis to Hold Third Quarter 2020 Conference Call on November 5

REDWOOD CITY, Calif., Sept.  08, 2020  (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company, announces that management will present at two upcoming virtual investment conferences:

Codexis to Present at Two Virtual Investment Conferences in September

R&D revenue from two customers helped the business to offset weakness from the coronavirus pandemic.

Codexis Dodges Coronavirus Slowdown in Q2

Codexis, Inc. (CDXS) CEO John Nicols on Q2 2020 Results - Earnings Call Transcript

News for Codexis Stock (CDXS)